Clinical trialNCT06375044RecruitingPhase 1Interventional

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

SponsorJiangsu Simcere Pharmaceutical Co., Ltd.Enrollment130Relapsed or Refractory Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Beijing Chaoyang Hospital Capital Medical University
Beijing, Beijing Municipality, China
Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China
Recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Recruiting
the First Affiliated Hospital Zhejiang University School of Medicine
Hanzhou, Zhejiang, China
Recruiting

United States

Mayo Clinic Arizona
Phoenix, Arizona, United States
Saurabh Chhabra, MD
Recruiting
Uc Irvine Health
Orange, California, United States
Polina Bellman, MD
Recruiting
Mayo Clinic Florida
Jacksonville, Florida, United States
Sikander Ailawadhi, MD
Recruiting
Dana Farber Cancer Institution
Boston, Massachusetts, United States
Not, yet, recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Shaji Kumar, MD
Recruiting
Icahn School of Medicine at Mount Sinai，the Tisch Cancer Institute
New York, New York, United States
Recruiting
Laura & Isaac Perlmutter Cancer Center at Nyu Langone Health
New York, New York, United States
Recruiting
University of North Carolina Hospitals at Hillsborough
Hillsborough, North Carolina, United States
Eben Lichtman, MD
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Jesus Berdeja, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SIM0500

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 May 2024
Primary completion: 30 Sept 2027
Completion: 30 Dec 2028
Last update posted: 11 Aug 2026
Registered enrollment: 130
Registry id: NCT06375044

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.